1 Bold Prediction for Viking Therapeutics in 2026

Viking Therapeutics has surfaced as a potential takeover target in 2026 amid heightened M&A interest in the anti‑obesity space because it is developing VK2735, a dual GLP‑1/GIP agonist being tested in both oral and subcutaneous forms. Its phase‑2 Venture trial showed strong efficacy (12.2% mean weight loss at 13 weeks) but a 20% discontinuation rate for adverse events, a signal that contrasts with favorable phase‑1 safety data and may reflect short trial duration and aggressive titration rather than insurmountable safety problems; a maintenance trial combining oral and subcutaneous dosing is already underway. Given recent bidding activity for obesity assets and the ability of larger pharma to manage complex development programs and data, acquirers could view Viking’s pipeline as undervalued, though definitive commercial and safety conclusions await larger, longer trials.

Analysis

Viking Therapeutics (VKTX) is flagged as a potential takeover target in 2026 because it is developing VK2735, a dual GLP-1/GIP agonist being tested in both oral and subcutaneous forms, and recent M&A activity in obesity assets (the Pfizer–Novo Nordisk bidding for Metsera) has elevated acquirers' appetite for such pipelines. The phase 2 Venture trial for oral VK2735 showed strong efficacy—mean 12.2% weight loss at 13 weeks—but a 20% discontinuation rate for adverse events in the treatment arm (versus 13% in placebo), which investors interpreted as a material safety signal. By contrast, Eli Lilly’s oral GLP-1 forglipron recorded a 10.3% adverse-event discontinuation in phase 3 Attain-1 over 72 weeks, highlighting that trial duration, titration pacing, and patient mix matter when comparing across studies. Viking’s phase 1 safety data were described as exemplary and the company has initiated a maintenance trial combining oral and subcutaneous VK2735, which, together with the complexity of the dataset, supports the thesis that a larger pharma buyer could extract value by optimizing titration or study design. Market sentiment is mildly positive and speculative; the primary near-term risks are the unresolved safety/discontinuation signal, short duration of the phase 2 data, and the uncertain timing and terms of any M&A interest.

Key Decisions for Investors

• Consider a small, event-driven position in VKTX to capture potential M&A upside but size it conservatively given the 20% treatment discontinuation signal,
• Monitor upcoming clinical readouts closely—particularly the maintenance combination trial results, detailed discontinuation causality, and any changes to titration protocols—before materially increasing exposure,
• Limit downside by setting exposure caps or hedges because value realization likely depends on either clearer long-duration safety/efficacy data or a strategic buyer willing to invest in additional development and trial optimization